Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial. In this clinical trial, zanidatamab demonstrated an objective response rate of 41.3% and a median duration of response of 15.5 months, while patients whose tumors showed strongest levels of HER2 overexpression experienced even greater benefit – a 51.6% response rate and a median duration of response of 18.1 months Initial trial...

Researchers have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor growth and resistance to KRAS inhibitors in patients with KRAS-mutant cancers. Blocking RASH3D19 in combination with KRAS inhibitors improved outcomes in preclinical models, suggesting this combination as a potential therapeutic strategy for patients with KRAS-mutant cancers. The study was led by Subrata Sen, Ph.D., deputy chair of Translational Molecular Pathology, and Hiroshi Katayama, Ph.D., associate professor of Translational Molecular...

Researchers have shown that DNA inflexibility, or rigidity, inside the nucleosome regulates the positioning of INO80. This highlights that the physical structure and shape of DNA, not just genetic information, are key components of DNA transcription. It also suggests that the Arp5 subunits may act as sensors that regulate INO80 remodeling depending on the shape of the DNA. The study was co-led by Blaine Bartholomew, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, and colleagues Post Views: 258

Researchers discovered that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models. The study was led by Pavlos Msaouel, M.D., Ph.D., and Giannicola Genovese, M.D., Ph.D., both associate professors of Genitourinary Medical Oncology; Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology; and Linghua Wang, M.D., Ph.D., associate professor of Genomic Medicine, associate member of the James P....

Researchers have performed a comprehensive evaluation of five artificial intelligence (AI) models trained on genomic sequences, known as DNA language models. These comparisons provide valuable insights into their strengths and weaknesses and offer a framework for selecting appropriate models based on specific genomic tasks. The study was led by Chong Wu, Ph.D., assistant professor of Biostatistics and affiliate of the Institute for Data Science in Oncology; and Peng Wei, Ph.D., professor of Biostatistics. Post Views: 285

Researchers have performed a comprehensive evaluation of five artificial intelligence (AI) models trained on genomic sequences, known as DNA language models. These comparisons provide valuable insights into their strengths and weaknesses and offer a framework for selecting appropriate models based on specific genomic tasks. The study was led by Chong Wu, Ph.D., assistant professor of Biostatistics and affiliate of the Institute for Data Science in Oncology; and Peng Wei, Ph.D., professor of Biostatistics. Post Views: 204

Patients with lower-risk myelodysplastic syndromes (MDS) experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations of azacitidine or decitabine. Final data from the trial was presented by Ian Bouligny, M.D., assistant professor of Leukemia.   “For patients with lower-risk MDS, a five-day duration of azacitidine was safe and effective, showing improved event-free survival and overall survival compared to three-day durations of azacitidine or decitabine,” Bouligny said. “We’ve seen firsthand how this approach improves...

Researchers have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression of the CD40 protein as a potential biomarker associated with improved overall survival (OS). The study was led by Francisco Vega, M.D., Ph.D., professor of Hematopathology, and Tania Sainz, graduate research assistant.   “The discovery of CD40 overexpression as a potential biomarker gives us a new lens to assess patient risk and opens the door to therapeutic...

In a Phase Ib/II trial led by Naval Daver, M.D., professor of Leukemia, patients with newly diagnosed CD123-positive acute myeloid leukemia (AML) who were unable to undergo intensive chemotherapy had strong response rates from the triplet combination of venetoclax, azacitidine and pivekimab sunirine (PVEK).   “This triplet regimen may represent a significant step forward for older patients with CD123-positive AML who are not candidates for intensive chemotherapy,” Daver said. “The remission and MRD rates we observed are very encouraging...

Memorial Hermann Health System today announced a $282.5 million expansion of Memorial Hermann Katy Hospital, designed to meet the needs of the region’s rapidly growing population and the rising demand for high-quality, patient-centered care, supported by leading-edge technology. Construction is scheduled to begin in late 2026. The centerpiece of the planned expansion is a new eight-story patient tower, which will include additional inpatient beds, advanced imaging services and a rooftop helipad for Memorial Hermann Life Flight®. Additional...